Terms: = Skin cancer AND SDHD, PGL1, 6392, ENSG00000204370, PGL, SDH4, CBT1, O14521 AND Prognosis
4 results:
1. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
[TBL] [Abstract] [Full Text] [Related]
2. sdhd promoter mutations are rare events in cutaneous melanomas but sdhd protein expression is downregulated in advanced cutaneous melanoma.
Pópulo H; Batista R; Sampaio C; Pardal J; Lopes JM; Soares P
PLoS One; 2017; 12(6):e0180392. PubMed ID: 28662141
[TBL] [Abstract] [Full Text] [Related]
3.
Zhang T; Xu M; Makowski MM; Lee C; Kovacs M; Fang J; Willems E; Trent JM; Hayward NK; Vermeulen M; Brown KM
Cancer Res; 2017 Apr; 77(7):1649-1661. PubMed ID: 28108517
[No Abstract] [Full Text] [Related]
4. Differences in cytokine levels in melanoma patients with and without redness (Brenner sign).
Mashiah J; Brenner S; Pessach Y; Barak V; Schachter J
Anticancer Res; 2009 May; 29(5):1793-6. PubMed ID: 19443406
[TBL] [Abstract] [Full Text] [Related]
